DOD Tuberous Sclerosis Complex Idea Development Award

The summary for the DOD Tuberous Sclerosis Complex Idea Development Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

DOD Tuberous Sclerosis Complex Idea Development Award: The Tuberous Sclerosis Complex Research Program (TSCRP) was established in 2002 to promote innovative research focused on decreasing the clinical impact of tuberous sclerosis complex (TSC). The mission of the TSCRP is to encourage innovative research aimed at understanding the pathogenesis of TSC and to translate these findings to the care of individuals with TSC. The FY11 TSCRP Idea Development Award supports high-impact, innovative research that will drive the field of TSC research forward. Preclinical studies are encouraged but clinical trials are not allowed. Important aspects of the Idea Development Award are as follows: The proposed research should have a significant impact on the concepts or methods that drive the field of TSC research. The proposed research is expected to make an important and original contribution to advancing TSC research and/or patient care. Research deemed innovative may represent a new paradigm, challenge existing paradigms, or look at existing problems from new perspectives or exhibit other uniquely creative qualities. Research may be innovative in study concept, research methods or technology, clinical interventions, or adaptations of existing methods or technologies. Research that represents an incremental advance on previously published work is not considered innovative. Preliminary data should be included that is relevant to the proposed project. The FY11 TSCRP strongly supports collaborative research between basic scientists and clinical researchers, and between academic scientists and biotechnology/pharmaceutical industry scientists. Collaborations that bring new perspectives from other disciplines or bring new investigators into the TSC field are also strongly encouraged.